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Abstract
Objective Biologics are indicated in rheumatoid arthritis (RA) in case of persistent high disease activity despite conventional
disease-modifying anti-rheumatic drugs (cDMARDs) or patients with contraindications to cDMARDs or poor prognostic factors.
The purpose of this study was to compare the prescription rates of biologics in Kuwaiti and non-Kuwaiti patients and to assess
whether this had an impact on disease activity and quality of life in RA patients.
Methods Data were extracted from the Kuwait Registry for Rheumatic Diseases. Adult patients who satisfied the ACR classi-
fication criteria for RA from four major hospitals in Kuwait were evaluated from February 2013 through May 2018. The
treatment agents, disease activity, and quality of life of Kuwaiti patients were compared with non-Kuwaiti patients.
Results A total of 1651 RA patients were included; 806 (48.8%) were Kuwaiti patients. Among Kuwaiti patients, 62.5% were on
biologic drugs in comparison with 14% of non-Kuwaiti patients. In comparison with non-Kuwaiti patients, Kuwaiti patients had
significantly lower numbers of swollen joints (p < 0.001) and disease activity score-28 scores (p = 0.02) and less steroid use
(p < 0.001) yet a significantly higher health assessment questionnaire-disability index (p < 0.001). Regression analysis showed
that DAS-28 scores were significantly associated with the treatment type (p < 0.001) and that nationality was significantly
predictive of the treatment type (p < 0.001).
Conclusion In the setting of easy accessibility to treatment for Kuwaiti patients, biologics were prescribed by rheumatologists at a
higher rate than for non-Kuwaitis. This may explain the lower disease activity and the lower rate of steroid use in Kuwaiti patients
than non-Kuwaitis.
Key points
• Significant discrepancies in the rates of prescribing biologic therapies between KP and NKP in Kuwait were observed.
• Several treatment outcomes were significantly better in the KP group than in the NKP group even after adjustment of
confounding factors.
• The poor access to biologic therapies was suggested to limit the effectiveness of RA treatments in the NKP group.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease that af-
fects 0.25 to 1% of the global population [1, 2]. In Kuwait,
around 1% of the population is estimated to have RA [3].
Although the exact pathogenesis of RA remains unclear, sev-
eral key players have been identified and targeted [4]. Several
biological drugs have been approved by the FDA for the treat-
ment of RA. These include drugs targeting tumor necrosis
factor (TNF-α), interleukin (IL)–1, IL-6, B lymphocytes,
and T lymphocyte co-stimulatory molecules. All these drugs
have shown marked efficacy in clinical trials, especially in
combination with methotrexate [5, 6].
In line with international guidelines [7, 8], the 2018 Kuwait
Association of Rheumatology guidelines recommended the use
of biologic therapy in (a) patients with early RA if they had
persistent moderate to high disease activity despite conventional
disease-modifying anti-rheumatic drugs (cDMARDs) and (b)
patients with established RA, especially thosewith an inadequate
response to cDMARDs or those with contraindications to
cDMARDs, high disease activity, or poor prognostic factors.
The guidelines further addressed the indications for TNF-
inhibitor (TNFi)– or non-TNFi-based biologic therapy [9].
The population in Kuwait is 4,237,029 with 70% of the pop-
ulation being expatriates (non-Kuwaitis) [10]. The Ministry of
Health provides all health services, including investigations and
treatment to Kuwaiti patients at no cost. This also applies to all
types of biologic treatments. Further, biologic therapy is provided
to Kuwaiti patients (KP) within an average of a week after being
evaluated by their treating rheumatologists. However, for non-
Kuwaiti patients (NKP), the system is more complicated as the
prescription has to go to a committee in a charity organization
where the case is studied from medical and financial aspects. If
approved, the charity organization will cover part of the cost
depending on the patient’s budget. This usually takes 6 to
12 months until the medication is available, depending on how
fast the paperwork is processed and the schedule of meetings to
study the case. The 2018 Kuwait Association of Rheumatology
guidelines were released in part to address the inequalities among
KP and NKP in terms of access to biologics, lower disease ac-
tivity, and better physical function [9].
This study is aimed at comparing the prescription rates of
biologic drugs to KP and NKP and at assessing whether the
process of providing biologic drugs to RA patients in Kuwait
affects disease activity and quality of life in KP and NKP.
Methods
Study design
Data were extracted from the Kuwait Registry for Rheumatic
Diseases (KRRD). The methods of data collection in this
registry were described in a previous article [3]. Adult patients
who satisfied the ACR classification criteria for RA [11] from
four major hospitals (Amiri Hospital, Farwaniya Hospital,
Mubarak Al-Kabeer Hospital, and Jahra Hospital) in Kuwait
were evaluated from February 2013 through September 2019.
Patients were divided into two groups: KP and NKP.
Informed consent was obtained from all study subjects, and
the study protocol was approved by the ethical committee at
the Faculty of Medicine, University of Kuwait, and the
Ministry of Health, Kuwait. All procedures performed involv-
ing human participants were in accordance with the ethical
standards of the institutional committees and with the 1964
Helsinki declaration and its later amendments or comparable
ethical standards.
Data and outcome measurements
Data on the following parameters were collected: demograph-
ic data, treatment agents, and outcomes. These outcomes in-
cluded the following: disease activity score-28 (DAS-28) [12],
visual analog scale (VAS) pain, tender joints, swollen joints,
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), physician and patient global assessment (GA) [13],
and health assessment questionnaire-disability index (HAQ-
DI) [14]. In the latter, patients reported the degree of experi-
enced difficulty in performing common daily activities such as
eating, dressing, and walking. The collected baseline data and
outcomes were compared between the KP and NKP groups,
using appropriate statistical methods.
Statistical analysis
The normality of data was checked using Shapiro-Wilk’s test.
Data were presented as count (%) or mean ± standard devia-
tion. Pearson’s chi-squared and Fisher’s exact tests were used
to compare between KP and NKP for the categorical vari-
ables. For numerical variables, a t test was used to compare
the means between KP and NKP. To test the associations
between the treatment type and DAS-28 scores between the
two groups after controlling the confounding factors, the gen-
eralized linear model (GLM) was employed using a logistic
regression approach. As patients’ characteristics differed
across cohorts, a logistic regression model was used to
adjust for baseline differences. The model adjusted for
age, gender, rheumatoid factor (RF), smoking, anti-
citrullinated peptide antibodies (ACPA), and disease du-
ration. Adjusted odds ratios (ORs) and 95% confidence
intervals (CIs) were used for logistic regression results.
The statistical significance level was set at ≤ 0.05. All
statistical analyses were conducted using STATA ver-
sion Stata software, version 15.1 SE.
Clin Rheumatol
Results
Baseline characteristics
A total of 1651 RA patients with 10,282 hospital visits
were enrolled in the current analysis, of whom 806
(48.8%) were Kuwaitis and 1024 (62%) were females.
The mean age of all patients was 53.8 ± 12.5 years, the
mean disease duration was 8.96 ± 6.73 years, 1174
(77.2%) had positive RF, and 864 (65.8%) had positive
ACPA. Of all patients, 622 (37.7%) were on biologic
therapy. In comparison with NKP, KP was significantly
older, with longer disease duration, and had more fe-
males, with a higher frequency of comorbidities and
secondary Sjogren’s syndrome, (p ≤ 0.001). However,
NKP had a significantly larger number of smokers and
ACPA positivity. Table 1 shows the baseline character-
istics of the overall population and a comparison be-
tween KP and NKP in terms of these characteristics.
Treatment patterns
Among KP (N = 806), 503 (62.4%), 270 (33.5%), and
142 (18.6%) were on biologic therapies, cDMARDs,
and steroids, respectively. Among NKP (N = 845), 119
(14.1%), 701 (83%), and 209 (26.4%) were on biologic
therapies, cDMARDs, and steroids, respectively. A com-
parison between the two groups showed a significantly
higher frequency of prescribing biological therapies in
the KP group and a higher frequency of prescribing
cDMARDs and steroids in the NKP group (p < 0.001).
Figure 1 summarizes the frequencies of prescribing dif-
ferent therapeutic categories in the two groups.
Treatment outcomes
Among all the patients in the study, mean DAS-28 and HAQ-
DI scores were 2.72 ± 1.28 and 0.99 ± 0.70, respectively. In
comparison with NKP, KP had a significantly lower number
of swollen joints (p < 0.001), lower DAS-28 scores (p = 0.02),
and less steroid use (p < 0.001) yet a significantly higher
HAQ-DI scores (p < 0.001). However, both groups were com-
parable in terms of the number of tender joints, VAS pain,
ESR, CRP, physician GA, and patient GA (Table 2). NKP
who are RF positive have higher DAS-28 than their peers in
the KP group (Fig. 2a). Similarly, NKP who are ACPA pos-
itive have higher DAS-28 than their peers in the KP group
(Fig. 2b).
Analysis using the GLM showed that DAS-28 scores were
significantly associated with the treatment type (beta = 0.18,
p < 0.001, 95% C.I. [0.11, 0.25]) after controlling for the con-
founding factors including age, disease duration, gender, RF,
smoking, and ACPA. In the same model, the interaction be-
tween DAS-28 and nationality was significantly predictive of
the treatment type (beta = − 0.26, p < 0.001, 95% C.I. [− 0.38,
− 0.13]). This means that the difference in DAS-28 scores
between the two groups can be explained by the difference
in the treatment type after controlling for the other con-
founders (Table 3).
Discussion
Despite the availability of biological therapy options in the
Middle East, there still is undertreatment of RA patients eligi-
ble for biologics. The suboptimal administration of biologics
for RA patients in the Middle East and North Africa (MENA)
is widely accounted for high medication costs and difficult
access to therapies. Only 2% of RA patients in the MENA
Table 1 Differences in
demographic and basic
characteristics between Kuwaiti
and non-Kuwaiti patient groups
Kuwaitis
N = 806
Non-Kuwaitis
N = 845
All Patients
N = 1651
p value
Gender: female 578 (71.7%) 446 (52.8%) 1024 (62.0%) < 0.001
Age in years 56.4 ± 13.2 51.4 ± 11.2 53.8 ± 12.5 < 0.001
RA duration 10.3 ± 7.53 7.61 ± 5.50 8.96 ± 6.73 < 0.001
Smoking 42 (7.23%) 85 (13.4%) 127 (10.4%) 0.001
Family history of a rheumatic disease 139 (25.0%) 80 (12.8%) 219 (18.6%) < 0.001
Comorbidities 537 (66.6%) 347 (41.1%) 884 (53.5%) < 0.001
2ry Sjogren’s 167 (24.6%) 81 (12.3%) 248 (18.6%) < 0.001
Positive RF 538 (73.3%) 636 (80.9%) 1174 (77.2%) 0.001
Positive ACPA 371 (60.5%) 493 (70.4%) 864 (65.8%) < 0.001
Positive ANA 180 (28.8%) 195 (28.3%) 375 (28.5%) 0.862
ANA antinuclear antibodies, ACPA anti-citrullinated peptide antibodies, RA rheumatoid arthritis, RF rheumatoid
factor
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region received TNFi compared with 40% of RA patients in
the USA [15]. A study in Doha revealed that 65% of Qatari
RA patients receive biologics; however, only 15% of eligible
non-Qatari patients receive biologics. Even with the high total
health expenditure per capita, the main reason for this discrep-
ancy was the lack of medical insurance for non-Qatari RA
patients [16].
The current study showed significant discrepancies in the
rates of prescribing biologic therapies between KP and NKP
in Kuwait. Moreover, several treatment outcomes were signif-
icantly better in the KP group than in the NKP group even
after adjustment of confounding factors including the number
of swollen joints, mean DAS-28 scores, and the number of
patients receiving steroids. Although these discrepancies did
not affect all the efficacy variables in our study, however, the
higher DAS-28 score reflected a higher disease activity in
NKP in Kuwait. A retrospective analysis of 2282 patients
showed that delays in the administration of biologic
DMARDs could result from delayed approvals by healthcare
insurers and the high cost of biologics paid through out-of-
pocket expenses. These factors resulted in inadequate
responses to therapy, which surprisingly did not affect the
acceleration of treatment in that patient population [17]. The
dose and duration of administered steroids were not of prima-
ry focus in our study; however, the well-known safety con-
cerns of high doses or long durations of steroid administration,
especially in RA patients, could have a clear impact on bone
density and structure on the long term [18]. The combined
impact of inadequate control of disease activity and safety
concerns of high steroid rates indicates the need for rapid
and realistic solutions to help change this situation in NKP.
Despite the NKP having a higher disease activity, their HAQ-
DI scores were lower than the KP. This may be explained by
their tolerance to pain and their desire to overcome their func-
tional limitations that may be caused by their disease. The
majority of the NKP in Kuwait are of low socioeconomic
status, and their need to work despite their disease is crucial
for their living.
The sociodemographic impact on the management of RA
was clearly observed in our study, represented in the NKP
with mainly out-of-pocket expenditures for biological thera-
py. In 2017, a retrospective study in the USA analyzed
Table 2 Differences in disease
activity and quality of life
between the KP and NKP groups
Kuwaitis
N = 806
Non-
Kuwaitis
N = 845
All Patients
N = 1651
p value
Number of tender joints 2.98 ± 6.04 2.85 ± 5.29 2.91 ± 5.67 0.645
Number of swollen joints 0.42 ± 1.79 1.11 ± 2.97 0.78 ± 2.49 < 0.001
VAS pain 1.71 ± 2.53 1.59 ± 2.38 1.65 ± 2.46 0.311
ESR 28.0 ± 22.4 29.6 ± 22.9 28.8 ± 22.7 0.167
CRP 5.31 ± 4.77 5.75 ± 5.00 5.54 ± 4.89 0.115
HAQ-DI 1.07 ± 0.72 0.81 ± 0.63 0.99 ± 0.70 < 0.001
Patient GA 1.69 ± 2.49 1.72 ± 2.42 1.71 ± 2.45 0.798
Physician GA 1.05 ± 1.79 1.17 ± 1.84 1.11 ± 1.82 0.190
DAS-28 2.64 ± 1.29 2.79 ± 1.27 2.72 ± 1.28 0.020
Steroid use 79 (9.8%) 147 (17.4%) 226 (13.7%) < 0.001
p values are significant at p < 0.05
DAS-28 disease activity score-28, VAS visual analog scale, ESR erythrocyte sedimentation rate, CRP C-reactive
protein, GA global assessment, HAQ-DI health assessment questionnaire-disability index
Fig. 1 Treatment patterns among
Kuwaiti and non-Kuwaiti patients
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medical expenditure data from 2009 to 2012. It highlighted
that the average out-of-pocket expenditure was the highest for
biological therapy being almost 28-fold more than the expen-
diture for DMARDs. The high cost of biologics negatively
affected the patient adherence to medications especially in
patients with no medical insurance or of low income [19]. In
this study, the poor access to biologic therapies was
documented to limit the effectiveness of RA treatments.
These results are concordant with previous studies in the lit-
erature; however, the barriers against the accessibility to these
drugs varied in different countries. For example, Orlewska
et al. performed a study in Central and Eastern Europe and
concluded that macroeconomic conditions and restrictive na-
tional guidelines were the main barriers against accessing bi-
ologic therapies [20]. In another study that surveyed 46
European countries, Putrik et al. found that patients in low–
socioeconomic class countries had less access to biologic
drugs, as well as worse RA treatment outcomes [21]. In
Greece, Souliotis et al. reported that travel difficulties, late
physician appointments, and drug shortage in hospitals in-
creasingly limit the patients’ access to treatments [22]. Other
factors such as the area of residence and low education class
negatively impacted access to biologic agents. Moreover, el-
derly patients had less access to these drugs in other studies
[23, 24].
To our knowledge, this is the first study to assess this as-
sociation in the Middle East. Kuwait has an atypical demo-
graphic profile in which the majority of residents are non-
Kuwais Non-Kuwais
Naonality
Kuwais Non-Kuwais
Naonality
ACPA
a
b
Fig. 2 a Non-Kuwaiti patients
who are rheumatoid factor
positive have higher disease
activity score-28 than their peers
in the Kuwaiti group. b Non-
Kuwaiti patients who are anti-
citrullinated peptide antibody
positive have higher disease
activity score-28 than their peers
in the Kuwaiti group
Table 3 Generalized linear model using logistic regression
Constant − 0.14 (− 0.58, 0.31)
DAS-28 0.18* (0.11, 0.25)
Age − 0.02* (− 0.03, − 0.01)
Disease duration − 0.07* (− 0.09, − 0.05)
Gender (male) 0.63* (0.45, 0.81)
RF (positive) − 0.49* (− 0.67, − 0.30)
Smoking (yes) − 0.52* (− 0.82, − 0.22)
ACCP (positive) 0.94* (0.78, 1.11)
Nationality (non-Kuwaitis) 3.32* (2.92, 3.72)
DAS-28 X nationality − 0.26* (− 0.38, − 0.13)
*p < 0.001
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Kuwaiti expatriates. The current laws allow free and immedi-
ate access to biologic drugs for KP, while it provides limited
access to NKP. This allowed testing the impact of treatment
accessibility within two diverse cohorts in the same country
where the main difference is access to treatment. This hypoth-
esis was further confirmed with logistic regression analysis
after adjustment for other potential confounders.
The results of the current study support the recent guide-
lines of the Kuwait Association of Rheumatology that recom-
mended addressing the inequality in accessing biologic thera-
pies among KP and NKP in Kuwait. These results and recom-
mendations should be conveyed to the policymakers and
stakeholders to take effective actions against this problem.
Another recommendation is not only to increase NKP access
to biologic therapies but also to accelerate access to these
drugs. Several studies have shown that delays in starting bio-
logic therapy were associated with more advanced disease and
worse RA treatment outcomes [17, 25].
Despite having a relatively large sample size, this study has
some limitations. First, this is a retrospective study, inherently
susceptible to different forms of bias, such as the recall bias
with family history. Second, recording data from four differ-
ent hospitals may introduce some heterogeneity related to
inter-operator variability in outcome assessment and possibly
different patient demographics. However, this adds to the
strength of the wider generalizability of the generated results.
Further, patients’ adherence to medications, the time from
prescription to the application of biologics, and the side effects
of drugs could not be extracted from the registry. These points
should be assessed in future studies, not only in Kuwait but
also in other Middle Eastern countries.
In conclusion, in the setting of easy accessibility to treat-
ment, biologics were prescribed by rheumatologists at a
higher rate than when approval was preceded by a strict and
long protocol. This may explain the lower disease activity and
the lower use of steroids in patients with rapid access to bio-
logic treatment.
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